Enterprise Value

6.446B

Cash

15.56B

Avg Qtr Burn

N/A

Short % of Float

3.01%

Insider Ownership

65.11%

Institutional Own.

17.59%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMIRNATY (BNT162b2) Details
COVID-19, Infectious disease

Approved

Quarterly sales

BNT316 (ONC-392) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 3

Data readout

Phase 3

Initiation

Phase 2

Data readout

BNT113 Details
Head and neck cancer, Human papillomavirus

Phase 2

Data readout

Autogene cevumeran (BNT122) (RO7198457) Details
Solid tumor/s, Colorectal cancer

Phase 2

Data readout

BNT116 +/- cemiplimab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

Phase 2

Data readout

Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details
Solid tumor/s, Non-small cell lung carcinoma, Bladder cancer, Melanoma

Phase 2

Interim update

BNT325 (DB-1305) Details
Non-small cell lung carcinoma, Cancer, Lung cancer, Solid tumor/s

Phase 1/2

Data readout

BNT323 (DB-1311) Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

BNT167 Details
Vaccine, Shingles

Phase 1/2

Update

BNT211 Details
Solid tumor/s, Cancer

Phase 1/2

Initiation

BNT164 Details
Vaccine, Tuberculosis

Phase 1

Data readout

BNT116 +/- cemiplimab Details
Solid tumor/s, Non-small cell lung carcinoma, Cancer

Phase 1

Update

Phase 1

Update